FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Versant Venture Capital IV, L.P. 		2. Issuer Name and Ticker or Trading Symbol

Ophthotech Corp. [ OPHT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

ONE SANSOME STREET, SUITE 3630 		3. Date of Earliest Transaction (MM/DD/YYYY)

1/14/2019
(Street)

SAN FRANCISCO, CA 94104
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   1/14/2019     J (1)    129709   A $2.2984   (1) 5142333   I   See footnote   (2) (3)
Common Stock   1/14/2019     J (1)    817   A $2.2984   (1) 32394   I   See footnote   (2) (4)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  On January 14, 2019, the Reporting Persons received an additional 130,526 shares of Ophthotech Corporation ("Ophthotech") common stock as a result of the post-closing adjustment as provided for in that certain Agreement and Plan of Merger dated October 30, 2018, by and among Ophthotech, Inception 4, Inc. and the other parties thereto. No additional consideration was paid for such shares. The Reporting Persons' right to receive additional shares became fixed and irrevocable on October 30, 2018, the effective date of the merger.
(2)  This report on Form 4 is jointly filed by Versant Venture Capital IV, L.P. ("VVC IV") and Versant Side Fund IV, L.P. ("VSF IV"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
(3)  These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. Brian G. Atwood, Samuel D. Colella, Ross A. Jaffe, William J. Link, Rebecca B. Robertson, Bradley Bolzon, Ph.D., Charles M. Warden, Kirk G. Nielsen, Thomas Woiwode and Robin L. Praeger are managing directors of VV IV and share voting and dispositive power over the shares held by VVC IV; however, they each disclaim beneficial ownership of such securities, except to the extent of their pecuniary interests therein.
(4)  These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. Brian G. Atwood, Samuel D. Colella, Ross A. Jaffe, William J. Link, Rebecca B. Robertson, Bradley Bolzon, Ph.D., Charles M. Warden, Kirk G. Nielsen, Thomas Woiwode and Robin L. Praeger are managing directors of VV IV and share voting and dispositive power over the shares held by VSF IV; however, they each disclaim beneficial ownership of such securities, except to the extent of their pecuniary interests therein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Versant Venture Capital IV, L.P.
ONE SANSOME STREET
SUITE 3630
SAN FRANCISCO, CA 94104
X

Versant Side Fund IV, L.P.
ONE SANSOME STREET
SUITE 3630
SAN FRANCISCO, CA 94104
X

Versant Ventures IV, LLC
ONE SANSOME STREET
SUITE 3630
SAN FRANCISCO, CA 94104
X


Signatures
/s/ Robin L. Praeger, Managing Director of Versant Ventures IV, LLC, general partner of Versant Venture Capital IV, L.P. 1/16/2019
** Signature of Reporting Person Date

/s/ Robin L. Praeger, Managing Director of Versant Ventures IV, LLC, general partner of Versant Side Fund IV, L.P. 1/16/2019
** Signature of Reporting Person Date

/s/ Robin L. Praeger, Managing Director of Versant Ventures IV, LLC 1/16/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
OPHTHOTECH CORP. (NASDAQ:OPHT)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 OPHTHOTECH CORP. 차트를 더 보려면 여기를 클릭.
OPHTHOTECH CORP. (NASDAQ:OPHT)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 OPHTHOTECH CORP. 차트를 더 보려면 여기를 클릭.